Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

1.8K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.8K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

1.3K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.3K
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

1.8K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
1.8K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

1.7K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.7K
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

1.8K
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.8K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

2.1K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The screening accuracy of the PROMIS® Anxiety measures in adults - A systematic review and multiple-thresholds meta-analysis.

Journal of psychosomatic research·2026
Same author

Test accuracy of the Overall Anxiety Severity and Impairment Scale (OASIS) for screening anxiety in adults - systematic review and multiple thresholds meta-analysis.

Journal of affective disorders·2026
Same author

State-Trait Anxiety Inventory (STAI) for detecting anxiety disorders in adults.

The Cochrane database of systematic reviews·2025
Same author

Beck Anxiety Inventory (BAI) for detecting anxiety disorders in adults.

The Cochrane database of systematic reviews·2025
Same author

Sensitivities and specificities of questionnaires and clinical signs and symptoms to predict daily life impairment after SARS-CoV-2 infection varied across different health sectors.

Journal of psychosomatic research·2025
Same author

Diagnostic accuracy and factorial structure of the questionnaire for the assessment of depression symptoms in primary care (DESY-PC).

Psychiatry research·2025
Same journal

Interventions to prevent or cease electronic cigarette use in children and adolescents.

The Cochrane database of systematic reviews·2026
Same journal

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
See all related articles

Related Experiment Video

Updated: Mar 7, 2026

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker
08:32

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker

Published on: December 18, 2014

23.5K

WITHDRAWN: Propranolol for migraine prophylaxis.

Klaus Linde1, Karin Rossnagel2

  • 1Centre for Complementary Medicine Research, Department of Internal Medicine II, Technical University Munich, Munich, Germany.

The Cochrane Database of Systematic Reviews
|February 18, 2017
PubMed
Summary
This summary is machine-generated.

Propranolol effectively treats short-term migraine attacks compared to placebo. However, long-term efficacy and safety data are limited, and it appears comparable to other migraine prophylactic drugs.

More Related Videos

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

18.8K
Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache
05:40

Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache

Published on: July 29, 2021

10.0K

Related Experiment Videos

Last Updated: Mar 7, 2026

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker
08:32

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker

Published on: December 18, 2014

23.5K
3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

18.8K
Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache
05:40

Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache

Published on: July 29, 2021

10.0K

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Propranolol is a widely prescribed medication for migraine prevention.
  • Migraine is a common neurological disorder impacting millions globally.

Purpose of the Study:

  • To evaluate the efficacy of propranolol versus placebo for migraine prophylaxis.
  • To assess if propranolol is as effective as other prophylactic migraine treatments.

Main Methods:

  • Systematic review and meta-analysis of randomized and quasi-randomized controlled trials.
  • Searched MEDLINE/PubMed and Cochrane Central Register up to May 2003.
  • Included 58 trials (5072 participants) comparing propranolol with placebo or other drugs for at least 4 weeks.

Main Results:

  • Propranolol demonstrated clear short-term efficacy compared to placebo in 26 trials.
  • No significant differences were found when comparing propranolol to calcium antagonists, other beta-blockers, or various other drugs in 47 trials.
  • Methodological quality was often unsatisfactory, with high dropout rates and insufficient analysis.

Conclusions:

  • Clear evidence supports propranolol's short-term effectiveness for migraine prophylaxis over placebo.
  • Long-term treatment effects and stability after discontinuation remain unclear.
  • Propranolol appears to have comparable efficacy and safety to other migraine prophylactic agents.